Impact of a Pharmacological Cardioversion With Vernakalant on the Management Cost of Recent Atrial Fibrillation in Belgium

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.08.1447
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pharmacological Cardioversion of Long-Lasting Atrial Fibrillation

Circulation Journal
MedicineCardiovascular MedicineCardiology
2007English

Cost Considerations in the Management of Atrial Fibrillation &Ndash; Impact of Dronedarone

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2012English

External Cardioversion in Patients With Persistent Atrial Fibrillation

Japanese Heart Journal
2003English

Efficacy and Safety of Intravenous Vernakalant for the Rapid Conversion of Recent-Onset Atrial Fibrillation: A Meta-Analysis

Annals of Noninvasive Electrocardiology
MedicineCardiovascular MedicinePhysiologyCardiology
2017English

Hemodynamic Effects of Vernakalant in Cardio-Surgical ICU-patients Treated for Recent-Onset Postoperative Atrial Fibrillation

Scientific Reports
Multidisciplinary
2020English

Paroxysmal Atrial Fibrillation: Choice of Cardioversion Therapy

Rational Pharmacotherapy in Cardiology
Cardiovascular MedicinePharmacologyCardiology
2007English

Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48

Clinical Cardiology
MedicineCardiovascular MedicineCardiology
2016English

Correct Technique Is Important in Cardioversion of Atrial Fibrillation

BMJ
1996English

Recent Advances in the Understanding and Management of Atrial Fibrillation: A Focus on Stroke Prevention

F1000Research
GeneticsMolecular BiologyPharmacologyBiochemistryMicrobiology ImmunologyMedicineToxicologyPharmaceutics
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy